cbdMD (YCBD) Income from Continuing Operations (2016 - 2025)
cbdMD (YCBD) reported Income from Continuing Operations of 283131.0 for Q4 2025, down 1975.66% on a YoY basis from 15095.0 in Q4 2024, and up 58.36% sequentially from 679968.0 in Q3 2025.
cbdMD (YCBD) Income from Continuing Operations (2016 - 2025) Analysis & Trends
cbdMD (YCBD) has 10 years of Income from Continuing Operations data on file, last reported at 283131.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 1975.66% year-over-year to 283131.0; the trailing twelve-month figure through Dec 2025 stood at 2339128.0 (up 13.0% YoY), and the FY2025 full-year result was 2040902.0, up 44.84% from the prior year.
- Income from Continuing Operations rose to 283131.0 in Q4 2025, from 679968.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1537288.0 in Q2 2021 to a low of 31634143.0 in Q2 2022.
- A 5-year average of 5696964.9 and a median of 1553603.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations tumbled 2157.79% in 2022 and soared 125.97% in 2024, its largest moves.
- Tracing YCBD's Income from Continuing Operations over 5 years: stood at 19160904.0 in 2021, then surged by 79.35% to 3956062.0 in 2022, then surged by 74.81% to 996501.0 in 2023, then soared by 101.51% to 15095.0 in 2024, then tumbled by 1975.66% to 283131.0 in 2025.
- Business Quant data shows YCBD's Income from Continuing Operations at 283131.0 in Q4 2025, 679968.0 in Q3 2025, and 895272.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | cbdMD | 4.82 Mn | 1.43 Mn | 3.00 Mn | -283,131.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -283,131.00 |
| Sep 30, 2025 | -679,968.00 |
| Jun 30, 2025 | -895,272.00 |
| Mar 31, 2025 | -480,757.00 |
| Dec 31, 2024 | 15,095.00 |
| Sep 30, 2024 | -152,799.00 |
| Jun 30, 2024 | 459,737.00 |
| Mar 31, 2024 | -3.01 Mn |
| Dec 31, 2023 | -996,501.00 |
| Sep 30, 2023 | -15.87 Mn |
| Jun 30, 2023 | -1.77 Mn |
| Mar 31, 2023 | -1.34 Mn |
| Dec 31, 2022 | -3.96 Mn |
| Sep 30, 2022 | -14.63 Mn |
| Jun 30, 2022 | -31.63 Mn |
| Mar 31, 2022 | -4.66 Mn |
| Dec 31, 2021 | -19.16 Mn |
| Sep 30, 2021 | -3.92 Mn |
| Jun 30, 2021 | 1.54 Mn |
| Mar 31, 2021 | -12.51 Mn |